Biopharma Funds Continue to Surge

The once beaten-down sector posted strong gains for the fourth straight month.


Bigstock photo

Most biopharma and life sciences hedge funds fared well in February, extending their winning streak to four months. Several posted double-digit gains for the month, and most others had increases in the mid- to upper single digits. As a result, most of the funds are outperforming the broader market.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.